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MiROvaR, a microRNA-based panel to predict early relapse/progression of ovarian cancer 
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Despite the efficacy of first-line treatment, risk of relapse/progression remains a challenge for most 
epithelial ovarian cancer (EOC) patients and development of a molecular predictor could be a 
valuable tool for patients’ stratification. Considering that a master layer of gene expression 
regulation is provided by microRNAs (miRNAs), we aimed to develop a miRNA-based molecular 
classifier able to predict progression in EOC patients. 
Methods 
We analysed miRNA expression profiles in three case materials collected at diagnosis: 179 samples 
from a MITO (Multicenter Italian Trial in Ovarian cancer) trial (OC179) were used as training set; 
263 samples from two of our centres (OC263) and 452 samples from The Cancer Genome Atlas 
EOC series (OC452), were used as validation sets. We defined progression-free survival (PFS) as 
the primary clinical endpoint and adapted a semi-supervised prediction method to the miRNA 
expression profile to define the risk of progression. The predictor’s prognostic impact was evaluated 
by multivariable analysis using a Cox regression model. 
Findings 
We developed a 35 miRNAs-based predictor of Risk of Ovarian Cancer Relapse/progression 
(MiROvaR) able to classify OC179 patients into high-risk (89 patients, median PFS 18 months) and 
low-risk (90 patients, median PFS 38 months) (HR 1·85, 95% CI 1·29–2·60, P<0·001). MiROvaR 
prognostic value was also significant in the two validation sets and it maintained independent 
prognostic impact in multivariable analyses adjusting for relevant clinical covariates (HR 1·48, 95% 
CI 1·03–2·1; P=0·036; HR 3·09, 95% CI 2·23–4·28, P<0·0001; and HR 1·41, 95% CI 1·11–1·79, 
P=0·0047 for OC179, OC263, and OC452, respectively). MiROvaR performance was confirmed in 
all Type-II and in the subset of high-grade serous cases present in the OC263 samples thus 
supporting its value in stratifying patients according to risk of progression regardless of the clinical–
pathological characteristics of the tumours at presentation. 
Interpretation 
MiROvaR is a potential predictor of EOC progression with an independent prognostic impact. 




Epithelial ovarian cancer (EOC) is a life-threatening disease characterised by late-stage presentation 
and high pathological and molecular heterogeneity.
1
 Standard treatment for EOC patients is 
aggressive primary surgery followed by platinum-based chemotherapy. Even for patients who 
achieve a pathologically complete response, maintaining a disease-free status remains a challenge. 
In fact, in most of the patients an incurable state of platinum-resistant progressive disease 
eventually restricts therapeutic options. Despite the impressive t advance in surgical approaches and 
drug development, EOC patients have experienced little improvement in overall survival in the last 
30 years,
2
 and the five-year survival rate for advanced-stage patients is still around 30%.
3
 Great 
efforts have been made to develop gene expression-based molecular signatures, but actually few 
molecular prognostic classifiers have been developed 
4-9
 even less have been externally validated 
and no one is clinically available for EOC. One reason lies in the fact that EOC is a genetically 
plastic disease evolving during progression with an impressive heterogeneity at the time of initial 
diagnosis. To classify EOC patients for risk of progression, we therefore decided to focus our 
attention to microRNAs (miRNAs) that act as a master layer of regulation for gene expression and 
whose number is at least one order of magnitude lower than that of genes. Indeed, despite seminal 
papers on EOC miRNA profiles have been published 
10-12
, no data on classification of EOC patients 
for risk of relapse/progression are at present available. With the assumption that relying on miRNA 
expression could be a feasible approach to develop a prognostic predictor, we analysed the miRNA 
expression profiles of 894 EOC samples (to our knowledge, the largest collection so far available) 
to develop a miRNAs-based predictor of risk of EOC relapse/progression. We further assessed 





Study design and participants 
Three chemo-naive case materials were used for this study.  
The training set OC179 was derived from the MITO-2 clinical trial (NCT00326456).
13
 Paraffin 
blocks from the primary tumours of patients enrolled for the MITO-2 trial 
13
 were provided by 17 
out of 43 centres participating to the trial. Of these, 305/549 blocks were excluded for lack of 
sufficient amounts of tumour for RNA extraction, 18 for the poor quality of extracted RNA, 10 
because the tumours derived from metastatic lesions, 30 because they were not chemo-naive 
(samples were collected at interval debulking surgery after three cycles of chemotherapy), and one 
for hybridisation failure. After clinical-pathological revision of the available paraffin blocks, RNA 
extraction, quality control and profiling on human miRNA arrays, 179 cases were eligible for data 
analysis (Appendix page 2 and 10). The MITO2 sub-population examined in the miRNA study, in 
comparison with the overall MITO2-trial population, contained a slightly lower number of patients 
not operated at baseline or with stage IV disease at diagnosis (see Appendix page 4). Accordingly, 
OC179 showed a longer progression-free survival (PFS) time (22·8 months, 95% CI 18–29 months 
vs 17·1 months, 95% CI 16–19·4) and OS (not yet reached; 95% CI 63–NA vs 56·6 months, 95% 
CI 50–68·2).  
Two independent series: the OC263 case material (collected at the Istituto Nazionale dei Tumori - 
Milan (INT-MI), and at the Centro di Riferimento Oncologico (CRO) Aviano) and the OC452 
(from the EOC-TCGA data set https://tcga-data.nci.nih.gov/tcga/ and 
5 
for clinical data), were 
identified as validation sets. The OC263 study population was obtained by combining all of the 
EOC cases profiled by using the Illumina microchip platform at INT-MI, namely the OC130 case 
material (see 
14
 for details) and the OC133 case material collected at CRO Aviano. All experimental 
and clinical information for OC452 and OC130 has been described previously 
5,14
 and are publicly 
accessible through the GEO series for OC130 (superseries GSE25204 including GSE25202, 
GSE25203, and GSE67819) and the TCGA website for OC452 (https://tcga-data.nci.nih.gov/tcga/). 
For OC133, freshly frozen tumour samples were collected from patients with primary EOC who 
underwent surgical resection, before any chemotherapeutic treatment, at CRO Aviano. All clinical 
data and complete follow-up information were available. Tumour staging and grading were in 
accordance with the International Federation of Gynecology and Obstetrics (FIGO) and the World 
Health Organisation (WHO) criteria, respectively. A pathologist (VC-Aviano), with specialised 
expertise in gynaecological pathology reviewed all OC133 pathological data confirming the 
pathological diagnosis and the required representative percentage of tumor in each sample. None of 
the tumor samples included in our analysis was macrodissected. Tumor representation among the 
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three sample collections is similar. The TCGA collection included samples with > 70% of tumor 
and < 20% necrosis (https://tcga-data.nci.nih.gov/tcga/ and 
15
). The same sample characteristics 
have been adopted for training set OC179 and for the validation set OC263: > 70% of tumor 
cellularity and < 20% necrosis. 
Signed consent was obtained from all of the patients included in the study. For both OC179 and 
OC263, the investigation was approved by the institutional review boards of participating 
institutions. In the case of OC263, the study was approved by the Independent Ethics Committee of 
the INT-MI, where the miRNA profiling was performed. In the case of OC179 derived from the 
MITO-2 clinical trial,
13
 sample collection for translational research purposes was carried out 
following the approval of a study amendment in 2011. The characteristics of patients included in the 
study are summarised in Table 1. 
 
Procedures. 
The procedures for the RNA extraction and quality controls of OC179 and OC133 (included in the 
OC263 validation set) and for the miRNA expression profiling of all the case materials analysed, 
are described in detail in the Appendix page 2 and summarised in Figure 1. The Minimum 
Information About a Microarray Experiment (MIAME)-compliant data reported in this publication 
have been deposited in gene expression omnibus of the NCBI,
16
 and are accessible through the 
GEO series using the superseries accession number GSE73583, including GSE73581 (OC179) and 
GSE73582 (OC133). 
The prognostic model was developed using the OC179 data as training set and the OC263 and 
OC452 data as validation sets. Analyses were performed using R statistical language version 3.1.0 
(URL http://www.R-project.org) and R/Bioconductor packages (http://www.bioconductor.org/). 
OC263 is a microarray meta-analysis of miRNA microarray data sets generated at INT-MI. The 
OC263 contains three published data sets, (GSE25202, GSE25203, and GSE67819),
14
 listing 130 
cases as well as the OC133 data set (GSE73582), that were integrated through the virtualArray 
R/BioConductor package.
17
 The data sets shared the same microarray chip version (Illumina 
Human_v2 MicroRNA) identifying 1146 miRNAs annotated on miRBase v12.0. The ComBat 
algorithm 
18
 was applied to the normalised and log2-transformed data matrices to reduce the 
likelihood of non-biological technical experimental biases causing batch effects. The resulting 
integrated data set was named OC263. 
OC452 contains the ovarian cancer miRNA microarray profile from the TCGA consortium. The 
level 1 raw data were downloaded along with the clinical annotations in November 2014 from the 
TCGA website (https://tcga-data.nci.nih.gov/tcga/). The miRNA expression profiling was 
performed on Agilent 8 x 15K Human microarrays and identified 799 miRNAs annotated on 
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miRBase 10. Data were normalised using the robust multiarray average algorithm (RMA). log2-
transformed, and filtered using the AgiMicroRna R package as described for the training set 
(Appendix page 2).  
The data pre-processing performed to enable a comparison of the three case materials is described 
in the Results section.  
Progression-free survival (PFS) was defined as the primary clinical endpoint. A semi-supervised 
prediction method involving principal component analysis developed by Bair and Tibshirani 
19
 
(available through the R package superpc [http://www-stat.stanford.edu/~tibs/superpc]) and already 
successfully applied to transcriptome data,
20
 was adapted to the miRNA expression profiles to 
identify a prognostic model. Briefly, the significance of each miRNA was measured based on a 
univariate Cox proportional hazards regression analysis of PFS versus the miRNA log expression 
level. The miRNA entering into the model were not fixed a priori but were selected on the basis of 
their FDR (false discovery rate) that defines the expected proportion of false positive results for the 
balancing of competing demands of sensitivity and specificity, avoiding data overfitting. Imposing a 
FDR < 0.1 corresponding to α<0.025, 35 miRNAs entered into the model then we expect a 
maximum of 4 miRNAs to be false positives. Subsequently, the principal component analysis was 
used to reduce the dimensionality of the miRNA included in the model. The first two principal 
components, capturing 74·2% of miRNA expression variability, were used to obtain a regression 
coefficient (weight) for each miRNA and develop a model (named MiROvaR) to calculate the 
prognostic risk score. The OC179 samples were classified as being at low or high risk of 
progression/relapse after a ten-time cross-validation approach as “internal validation”. Risk 
classification was based on the median index values obtained in the set comprising 90% of the cases 
(training), with the remaining 10% of the omitted cases (test) classified according to this value. All 
cases were stratified after reiteration of the entire procedure, omitting a different 10% of cases until 
each case was excluded. The miRNAs entered into the different cross-validation sets were reported 
as the percentage of cross-validation support, assessing the percentage in the 10-cross-validated set 
in which the specific miRNA was selected. 
The prognostic risk index for each patient can be computed by the following formula:  
∑iwi xi + 3·196617, 
where wi and xi are the weight and logged miRNA expression for the i-th miRNA, respectively. A 
new sample was predicted as being at high (low) risk if its prognostic index was larger than (smaller 
than or equal to) 0·07359 which is the median value obtained in cross-validation. 
The capability of the model to predict PFS was evaluated through Kaplan–Meier curves and the 
log-rank test. A 1000-permutations test following a procedure known as “random shuffling” was 





survival data were randomly reassigned among the cases and the entire survival risk prediction 
process was repeated, assessing the null-distribution of the log-rank test. The tail area of the null-
distribution beyond the log-rank statistic of the real data estimates the permutation significance to 
test the null-hypothesis of the absence of a relationship between PFS and miRNA expression.
22
 The 
permutation test based on 1000 permutations reached P value=0·001. 
Performance of MiROvaR was evaluated by ROC curves, details on method are reported in 
Appendix page 2. 
 
Outcomes  
PFS was defined as primary end-point since the main goal of the predictor was to identify early 
relapsing patients. PFS was defined as the time interval (in months) between the date of random 
assignment (OC179) or the date of surgery (OC263 and OC452) and the date of progression or 
death, whichever occurred first, or the date of last follow-up for patients alive without progression. 
The proportion of cases that relied on date of death for PFS was; 4 out of 124 events for the OC179 
training set: 7 out of 195 events for the OC263 validation set 1 and 2 out of 327events for the 
OC452 validation set 2. Since the training set OC179 derived from the MITO2 clinical trial (see 
Appendix page 10), for this analysis we used the same PFS definition which started from the date of 
randomization as an ascertained rule in randomized trials (see Appendix page 3 for details). For 
OC179 case material, time between randomization and surgery is 1 month (mean, SD=0·46, range 
0·23-2·56 months). 
Overall survival (OS) was defined as secondary endpoint and was defined as the time (in months) 
between the date of random assignment (for OC179) or the date of surgery (for validation sets) and 
the date of death or the date of last contact for surviving patients. Median follow-up times were 73, 
44, and 56 months for OC179, OC263, and OC452 case materials, respectively; see Table 1 and 
details in Appendix page 3.  
 
Statistical analysis 
PFS and OS curves were reported according to the Kaplan–Meier method and were compared with 
the log-rank test. Median estimates, with 95% confidence intervals (CI), were also reported. A Cox 
univariate model was used to estimate the hazard ratio (HR) for each relevant prognostic variable. 
Multivariable analysis using a Cox regression model was used to evaluate the prognostic impact of 
MiROvaR in the context of concomitant effects of other known prognostic factors (stage and 
residual disease). The validity of proportional hazards assumption for a Cox model fit has been 
tested by evaluation of scaled Schoenfeld residuals. The choice of the covariates to be used in the 
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model was based on several reasons. First, we tried to select, among the variables with known 
prognostic value, those considered as the stronger ones in terms of PFS prediction in order to have a 
number of covariates not too high, adequate to the limited sample size of the OC179 training set. 
Second, we tried to avoid variables with subgroups very small based on current definitions (eg 
grading). Third, we avoided subjective variables (eg. performance status). Fourth, we avoided 
variables not available in the validation sets (eg. performance status not available in OC263, 
histology not informative in the TCGA set where there are only high grade serous tumors). As for 
age, that in any case is not considered a prognostic factor, its eventual use would not significantly 
change the result.  
Eventually, the covariates that we used for multivariable analyses were FIGO stage and residual 
disease after primary surgery.  Based on the extent of residual disease after primary surgery, the 
patient population was divided into three groups: no evident residual disease (NED), minimal 
residual disease (mRD, residual tumour smaller than 1 cm), and gross residual disease (GRD, 
residual tumour larger than 1 cm). They were then classified into two categories for further analysis: 
optimal debulking (OD, includes patients NED or with mRD) and suboptimal debulking (SOD, 
residual tumour larger than 1 cm). We choose the codification OD vs. SOD to be consistent with the 
paper reporting the MITO2 clinical trial final analysis 
13
 and to avoid small subgroups that might 
derive from using a 3-category codification. For both univariate and multivariable analyses, stage 
and surgical debulking were coded as dichotomous indicator variables (stage III /IV vs stage I/II, 
SOD vs OD). However a multivariable analysis for PFS was performed also coding residual disease 
as a three-levels (NED, mRD, GRD) categorical variable. Patients were then grouped based on 
similar clinical and pathological characteristics (see Table 1). The chi-square test was used to 
analyse the distribution of MiROvaR high-risk and MiROvaR low-risk patients in relation to 
clinical and pathologic variables. A P value <0·05 was considered significant. 
All analyses were carried out using R statistical language version 3.1.0 (URL http://www.R-
project.org). Graphs were generated using R or GraphPad PRISM (version 5.02) software. 
 
Role of the funding source 
No sponsor was involved in the study design, data collection, analysis and interpretation, in writing 
the manuscript, and in the decision to submit for publication. The following author had access to the 
raw data: MB, SC, MDM, FP, SP, LDC and DM. The corresponding author had full access to all the 






The case materials used to develop the miRNA-based molecular predictor of PFS are summarised in 
Figure 1. Patients’ characteristics and Kaplan–Meier curves are detailed in Table 1 and Appendix 
page 11, respectively. Overall, 894 EOC cases were analysed at the time of diagnosis. We 
performed accurate data pre-processing to allow the best comparison among the different platforms 
and chip arrays. The OC179, OC263, and OC452 miRNA array data were separately filtered to 
exclude miRNAs which were not detectable in all samples. Data matrices of 921, 706, and 661 
miRNAs, respectively were obtained. Since each data set was designed on different miRBase 
releases, each platform was re-annotated on miRBase release 21·0 (June 2014; 
http://www.mirbase.org/) at the sequence level. Putative miRNAs, sequences identifying virus 
miRNAs, non-mature miRNAs, or probe-sets unable to distinguish the members of a miRNA 
family and those discontinued through different miRBase versions were excluded. A list of 385 
unique miRNAs (Appendix page 5) was finally prepared and shared among the platforms and 
checked using the miRBase Traker tool (www.mirbasetracker.org) 
23
 to avoid confounding miRNA 
nomenclature.  
On the basis of the defined algorithm and after a 10-time cross validation, we developed a model 
containing 35 unique miRNAs whose expression significantly contributed to defining the risk of 
disease progression (Figure 2). Among the 35 identified miRNAs, 16 were associated with better 
prognosis (putative oncosuppressive miRNAs) and 19 with worse prognosis (putative oncogenic 
miRNAs) (Figure 2 and Table 2). The 35 miRNAs-based predictor of Risk of Ovarian Cancer 
Relapse/progression was named MiROvaR. 
MiROvaR applied to OC179 clearly separated 89 high- and 90 low-risk patients (HR 1·85, 95% CI 
1·29–2·6; P<0·0001) (Figure 3A and Table 3). ROC analyses were used to evaluate MiROvaR 
performance. The average AUC over 10-time cross-validation reaches a value of 0·68 with an 
acceptable standard deviation (+/- 0·02) confirming the good performance of our model in OC179 
(Appendix page 12). When challenged against validation sets, MiROvaR was able to stratify 
patients for their risk of progression with significantly different PFS times. One hundred and forty 
one MiROvaR high-risk (median PFS=12 months, 95% CI 10–13), and 122 MiROvaR low-risk 
(median PFS=34 months, 95% CI 26–45) patients were identified in the OC263 (Figure 3B) cohort 
while 283 MiROvaR high-risk (median PFS=15 months, 95% CI 14–18) and 169 MiROvaR low-
risk (median PFS=19 months, 95% CI 17–27) patients were detected in the OC452 cohort (Figure 
3C). The predictive value of MiROvaR was validated in both case materials: HR 3·16, 95% CI 2·3–
4·3, P<0·0001 for OC263 and HR 1·39, 95% CI 1·1–1·74, P=0·0047 for OC452 (Table 3) with 
AUC = 0·72 (SD ±0·01) and 0·58 (SD ±0·02) in OC263 and OC452, respectively (Appendix page 
11 
 
12). In all three series, advanced stage at diagnosis and sub-optimal debulking after primary surgery 
were, as expected, significantly associated with progression in univariate analysis (Table 3). 
Importantly, MiROvaR maintained its independent prognostic impact in all series when analysed in 
multivariable analysis adjusting for these clinical covariates although its impact on OC452 was less 
impressive (Table 3 and Appendix page 6). MiROvaR ability to stratify patients’ OS in all case 
materials is reported in Appendix pages 7 and 13. No interactions were observed between 
MiROvaR and the type of treatment (carboplatin plus taxane vs carboplatin plus pegylated 
doxorubicine) in the OC179 set (p for interaction = 0·62). A significant association of MiROvaR 
high risk was observed with advanced stage in the OC179 data set and with residual disease in the 
OC263 series (Appendix page 8). 
When compared with the OC452 (EOC-TCGA) validation set selected for high-grade serous 
ovarian cancer (HGSOC), the OC263 validation set was more heterogeneous in histotype and 
grading (see Table 1). We confirmed the independent predictive value of MiROvaR by analysing 
the 230 Type-II (Figure 4A and Table 4), and the 185 HGSOC (Figure 4B and Table 5) cases 
present in OC263. MiROvaR performance was good also in these two sub-sets of patients with 
AUC 0·72 (SD ± 0·.02) and 0·71 (SD ± 0·01) for Type-II and HGSOC, respectively (Appendix 
page 12). The analysis of Type II sub-set was done taking into consideration the new proposed 
classification of EOC that, besides HGSOC, includes in this sub-set also endometroid high grade, 








Identification of EOC patients with very unfavorable prognosis remains an urgent clinical need to 
improve the design of tailored therapy. The molecular predictor, MiROvaR, described in this study, 
and developed on a training set of 179 EOC cases, was able to stratify patients for their risk of 
relapse/progression with significantly different PFS. The identification of molecular classifiers like 
MiROvaR is based on an a priori choice of the outcome of interest. Since the main goal of our 
predictor was to identify early relapsing patients, we defined PFS as the more appropriated end 
point. PFS is widely accepted as a reasonable end-point in ovarian cancer 
25
, both clinically and in 
terms of new drug development, particularly in the first-line of treatment due to the fact that post-
progression survival may be quite long and affected also by different and heterogeneous second-line 
treatments diluting the differences eventually seen in PFS. MiROvaR was able to separate 
subgroups with different outcome in two independent validation sets, OC263 collected in our 
Institutions including both frozen and FFPE samples and TCGA relaying on frozen tissues only. We 
were however able to demonstrate that data obtained on frozen samples could be highly reproduced 
in FFPE samples and vice versa. 
14 
Although with a less impressive power, its value was confirmed 
also in the TCGA data set, the only so far available public collection with fully annotated clinical 
data that we use as second validation set, thus underlying MiROvaR ability to add significant 
prognostic information. 
Importantly, MiROvaR  retained its independent prognostic impact in multivariable analysis. In 
order to have a number of covariates adequate to the sample size of the OC179 training set, we 
selected among the known prognostic clinical variables for EOC those considered as the stronger 
ones in terms of PFS prediction (i.e. FIGO stage and residual disease). MiROvaR showed a good 
performance despite the criteria adopted for residual disease categorization and even if applied to 
heterogeneous populations of patients, thus supporting its value in stratifying patients according to 
their risk of progression, regardless of the clinical–pathological characteristics of their tumours at 
presentation.. With MiROvaR we aimed to develop a widely useful tool that could encompass the 
biological/molecular differences among the histological sub-types of ovarian cancers. For this 
reason we decided not to rely on possibly miRNA-driven patients segregation according to 
histological characteristic and MiROvaR validation in data sets with different mix of patient 
characteristics, strengthen its potential use. However, its validity in homogeneous sub-group of 
patients was confirmed in TCGA dataset that relies on HGSOC only, and in OC263 when 
considering HGSOC and type II patients which exclude low grade serous ovarian cancer, low grade 
endometrioid, clear cell and mucinous ovarian cancer. These tumor types (Type I) are rare and 
poorly represented and would rather benefit of a dedicated study. 
13 
 
The subgroup of patients with a very unfavorable prognosis identified by MiROvaR might be 
candidate to more aggressive strategies (possible addition of bevacizumab and/or maintenance 
treatment). However, the ability of more aggressive strategies to improve the prognosis of 
MiROvaR-high-risk patients should be independently demonstrated before saying that MiROvaR 
can guide treatment selection. For instance we could not predict response to therapeutic treatments 
in the analyzed case materials since interactions of potential predictive qualifiers and treatment can 
only be studied in randomized trials. In this study, OC179, derived from MITO2 randomized 
clinical trial, represents the only data set where such an analysis could be performed and yielded 
negative results. Within this dataset there is also a power issue related to the sample size, so we can 
only say that this analysis does not generate any hypothesis worth of further testing in terms of 
interaction with treatment arms (conceptually antracycline vs taxane). 
From a molecular point of view, one limit of the functional interpretation of miRNA profiles is due 
to their regulatory role, as each miRNA could regulates numerous genes and the fine tuning of each 
gene could be different and tissue specific. As specified below, for most of the miRNAs included in 
MiROvaR, their key role as central nodes in biological processes has been already identified. 
MiROvaR contains 35 unique miRNAs with an individually different relevance and different 
impact on patients’ prognosis. Among the 16 miRNAs that gave 100% of cross validation support 
to the MiROvaR predictor, 13 were associated with favourable prognosis and 3 with poor 
prognosis. Considering the increasing MiROvaR risk of progression, all of the 13 miRNAs 
individually associated with favourable prognosis and the 3 miRNAs associated with poor 
prognosis were down-modulated and up-modulated, respectively (see Figure 2). This suggests that 
the maintenance/loss of potentially oncosuppressive miRNAs has a greater impact on EOC 
prognosis than the expression/loss of potentially oncogenic miRNAs, in line with the observation 
that most miRNAs exert an oncosuppressive role and are consequently mostly down-regulated in 
cancer.
26
 Available literature data about their biological role in EOC essentially confirmed our 
assumptions, although confirmation of the roles of the 3 putative oncogenic miRNAs is limited. 
Indeed, miR-193a-5p and miR-30b-3p were up-modulated, respectively, in EOC refractory to neo-
adjuvant chemotherapy 
27
 and in low-grade serous EOC compared to fallopian tube.
28
 Although 
miR-29c-5p has been implicated in the regulatory network related to the mesenchymal subtype of 
HGSOC,
29
 information is currently not available concerning its prognostic role in EOC. An 
oncosuppressive role for miR-29c has, however, been described in colorectal cancer.
30
 In contrast, 
mature data are available for the majority of the 13 putative oncosuppressive miRNAs. In particular, 
we have previously shown that loss of a ChrXq27.3 miRNA cluster, totally included in the 
MiROvaR main contributors (miR-508-3p, miR-509-5p, 514a-3p, miR-506-3p, miR-507, miR-509-
14 
 
3p, miR-513b-5p and miR-513a-5p), is associated with EOC early relapse 
14
. This cluster also 
appears to be down-modulated in the majority of MiROvaR high-risk patients (see Figure 2). A 
deep functional characterisation of miR-506, a key node of the master miRNA regulatory network 
related to mesenchymal EOC subtype,
29,31
 linked its expression at tumor level 
29
 to: (i) inhibition of 
EOC proliferation and induction of senescence,
32
 (ii) suppression of the epithelial–mesenchymal 
transition (EMT),
33
 and (iii) an increase in the response to chemotherapy,
34
 thus confirming its 
oncosuppressive role. Besides the ChXq27.3 miRNA cluster, MiROvaR included almost all the 
members of the miR-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429), which 
are known EMT regulators,
35,36
 as main contributors and loss of miR-200c expression has been 
associated with relapse even in stage I EOC.
11
 Also this miRNA family appears to be down-
modulated in the majority of MiROvaR high-risk patients (see Figure 2). Only in the case of miR-
592 no data are available concerning its prognostic role in EOC, its expression was, however, 
predictive of improved outcome in three different cohorts of colorectal cancers 
37
 thus supporting an 
oncosuppressive role. 
Although definitive data about the biological and prognostic role of all of the miRNAs included in 
MiROvaR are not yet available in EOC, the main impact on the prediction of early recurrence 
appears to be associated with EMT regulation. The high number of miRNAs regulating EMT 
included in our predictor (miR-506 family and miR-200 family) underlines the relevance of cellular 
reprogramming to a more mesenchymal phenotype as an initiating event during EOC spread and 
progression. Furthermore, a very recent paper underlined the relevance of loss of miR-200 family 
members in contributing to recurrent lung metastases after chemotherapy in a breast cancer model, 
thus suggesting the potential for an EMT-targeting strategy associated with conventional therapy.
38
  
By applying a rigorous methodology, we have developed a strong predictor for EOC risk of 
progression/relapse by using three independent data sets for which mature follow-up data were 
available. We assessed its performance and validated its potency in two independent data sets with 
impressive results in the first validation set (OC263). We are aware that our analysis, by relying on 
the 385 miRNA shared by all the used platforms, may have lost other important miRNAs. However, 
our work is one of the few attempts in integrating the existing data building a single model that 
could be fully validated trying to overcome one of the limitation related to miRNA analysis which 
rely on the use of different platforms and different annotated lists. The applicability of MiROvaR as 





 which include: i) the identification of an appropriate methodology (microarray, 
RTqPCR, Nanostring …); ii) design of specific probes based on the sequences tested in the 
15 
 
microarray chips; iii) validation on independent cohorts of patients with full clinical annotation 
available.  
We remark that our model is completely free to the scientific community and if other pivotal 
miRNAs will be indentified in future, they can be tested and integrated into MiROvaR. An 
opportunity to assess MiROvaR performance will be the availability of samples for translational 
purposes retrospectively collected in the MITO7 clinical trial 
41
 and prospectively collected in the 
MITO16 programs (NCT01706120 and NCT01802749); in the latter, tumor collection has become 





All the authors have been involved in this research manuscript. SC, GB, SP, and DM had the idea 
for the study. MB, SC, LDC, FP and DM designed the experiments. DC, SL, GS, GC, DR 
centralized and prepared samples from OC179; FR, DL, MLC, MB, SC, and DM collected samples 
and clinical data for OC130 dataset included into OC263 validation set. GT, EC, RS, VC collected 
samples and clinical data for OC133 dataset included into OC263 validation set. FR, DL, RS, GS, 
AS, PS, EB, VM and SP obtained samples and clinical data. SL, GS, MLC, VC, GFZ, MC did the 
hystopathological analysis. LDC did the microarray analysis and submission of data to GEO. MB, 
LDC and MDM did the bioinformatic and statistical analyses. MB, SC, DM, LDC, SP and FP 
critically revised all the data. All the authors reviewed the manuscript and approved the final 
version. 
 
CONFLICT OF INTEREST  
All the authors declare no competing interests.  
 
ACKNOWLEDGMENTS 
We thank the Biorepository personnel at the Fondazione IRCCS Istituto Nazionale dei Tumori 
whose activity made this study possible in particular Dr. Silvia Veneroni for valuable contribution 
in tissue sample collection. The Italian Association for Cancer Research (AIRC: IG-10302 to SC, 
IG-17475 to DM, Special Program 12162 to SC and IG-5776 to SP) and CARIPLO Foundation 






 1.  Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet 2014; 384: 
1376-88. 
 2.  Vaughan S, Coward JI, Bast RC, Jr. et al. Rethinking ovarian cancer: recommendations for 
improving outcomes. Nat Rev Cancer 2011; 11: 719-25. 
 3.  Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29. 
 4.  Tothill RW, Tinker AV, George J et al. Novel molecular subtypes of serous and 
endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008; 14: 5198-
208. 
 5.  Kang J, D'Andrea AD, Kozono D. A DNA repair pathway-focused score for prediction of 
outcomes in ovarian cancer treated with platinum-based chemotherapy. J Natl Cancer Inst 
2012; 104: 670-81. 
 6.  Tan TZ, Miow QH, Huang RY et al. Functional genomics identifies five distinct molecular 
subtypes with clinical relevance and pathways for growth control in epithelial ovarian 
cancer. EMBO Mol Med 2013; 5: 983-98. 
 7.  Verhaak RG, Tamayo P, Yang JY et al. Prognostically relevant gene signatures of high-
grade serous ovarian carcinoma. J Clin Invest 2013; 123: 517-25. 
 8.  Riester M, Wei W, Waldron L et al. Risk prediction for late-stage ovarian cancer by meta-
analysis of 1525 patient samples. J Natl Cancer Inst 2014; 106 (5). pii: dju048. 
 9.  Konecny GE, Wang C, Hamidi H et al. Prognostic and therapeutic relevance of molecular 
subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst 2014; 106: dju249. 
 10.  Iorio MV, Visone R, Di Leva G et al. MicroRNA signatures in human ovarian cancer. 
Cancer Res 2007; 67: 8699-707. 
 11.  Marchini S, Cavalieri D, Fruscio R et al. Association between miR-200c and the survival of 
patients with stage I epithelial ovarian cancer: a retrospective study of two independent 
tumour tissue collections. Lancet Oncol 2011; 12: 273-85. 
 12.  Vecchione A, Belletti B, Lovat F et al. A microRNA signature defines chemoresistance in 
ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci U S A 2013; 110: 
9845-50. 
 13.  Pignata S, Scambia G, Ferrandina G et al. Carboplatin Plus Paclitaxel Versus Carboplatin 
Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian 
Cancer: The MITO-2 Randomized Phase III Trial. J Clin Oncol 2011; 29: 3628-35. 
 14.  Bagnoli M, De Cecco L, Granata A et al. Identification of a chrXq27.3 microRNA cluster 
associated with early relapse in advanced stage ovarian cancer patients. Oncotarget 2011; 2: 
1265-78. 
 15.  Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian 
carcinoma. Nature 2011; 474: 609-15. 
 16.  Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and 
hybridization array data repository. Nucleic Acids Res 2002; 30: 207-10. 
 17.  Heider A, Alt R. virtualArray: a R/bioconductor package to merge raw data from different 
microarray platforms. BMC Bioinformatics 2013; 14: 75. 
 18.  Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data 
using empirical Bayes methods. Biostatistics 2007; 8: 118-27. 
 19.  Bair E, Tibshirani R. Semi-supervised methods to predict patient survival from gene 
expression data. PLoS Biol 2004; 2: E108. 
 20.  De Cecco L, Bossi P, Locati L, Canevari S, Licitra L. Comprehensive gene expression meta-
analysis of head and neck squamous cell carcinoma microarray data defines a robust 
survival predictor. Ann Oncol 2014; 25: 1628-35. 
 21.  Radmacher MD, McShane LM, Simon R. A paradigm for class prediction using gene 
expression profiles. J Comput Biol 2002; 9: 505-11. 
18 
 
 22.  Crijns AP, Fehrmann RS, de JS et al. Survival-related profile, pathways, and transcription 
factors in ovarian cancer. PLoS Med 2009; 6: e24. 
 23.  Van Peer G., Lefever S, Anckaert J et al. miRBase Tracker: keeping track of microRNA 
annotation changes. Database (Oxford ) 2014; 2014: bau080. 
 24.  Shih I-M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological 
and molecular genetic analysis. Am J Pathol 2004; 164: 1511-8. 
 25.  Stuart GC, Kitchener H, Bacon M et al. 2010 Gynecologic Cancer InterGroup (GCIG) 
consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian 
Cancer Consensus Conference. Int J Gynecol Cancer 2011; 21: 750-5. 
 26.  Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. 
Nature 2005; 435: 834-8. 
 27.  Mariani M, McHugh M, Petrillo M et al. HGF/c-Met axis drives cancer aggressiveness in 
the neo-adjuvant setting of ovarian cancer. Oncotarget 2014; 5: 4855-67. 
 28.  Zhang S, Lu Z, Unruh AK et al. Clinically relevant microRNAs in ovarian cancer. Mol 
Cancer Res 2015; 13: 393-401. 
 29.  Yang D, Sun Y, Hu L et al. Integrated Analyses Identify a Master MicroRNA Regulatory 
Network for the Mesenchymal Subtype in Serous Ovarian Cancer. Cancer Cell 2013; 23: 
186-99. 
 30.  Zhang JX, Mai SJ, Huang XX et al. MiR-29c mediates epithelial-to-mesenchymal transition 
in human colorectal carcinoma metastasis via PTP4A and GNA13 regulation of beta-catenin 
signaling. Ann Oncol 2014; 25: 2196-204. 
 31.  Sun Y, Guo F, Bagnoli M et al. Key nodes of a microRNA network associated with the 
integrated mesenchymal subtype of high-grade serous ovarian cancer. Chin J Cancer 2015; 
34: 28-40. 
 32.  Liu G, Sun Y, Ji P et al. MiR-506 suppresses proliferation and induces senescence by 
directly targeting the CDK4/6-FOXM1 axis in ovarian cancer. J Pathol 2014; 233: 308-18. 
 33.  Sun Y, Hu L, Zheng H et al. MiR-506 inhibits multiple targets in the epithelial-to-
mesenchymal transition network and is associated with good prognosis in epithelial ovarian 
cancer. J Pathol 2014; 235: 25-36. 
 34.  Liu G, Yang D, Rupaimoole R et al. Augmentation of response to chemotherapy by 
microRNA-506 through regulation of RAD51 in serous ovarian cancers. J Natl Cancer Inst 
2015; 107: djv108. 
 35.  Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial 
phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes 
Dev 2008; 22: 894-907. 
 36.  Mezzanzanica D, Bagnoli M, De Cecco L, Valeri B, Canevari S. Role of microRNAs in 
ovarian cancer pathogenesis and potential clinical implications. Int J Biochem Cell Biol 
2010; 42: 1262-72. 
 37.  Boisen MK, Dehlendorff C, Linnemann D et al. Tissue microRNAs as predictors of 
outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and 
Oxaliplatin with or without Bevacizumab. PLoS One 2014; 9: e109430. 
 38.  Fischer KR, Durrans A, Lee S et al. Epithelial-to-mesenchymal transition is not required for 
lung metastasis but contributes to chemoresistance. Nature 2015; 527: 472-6. 
 39.  Micheel CM, Nass SJ, Omenn GS, Editors. Commitee on the review of Omics-based tests 
for predicting patient outcomes in clinical trials; Board on health care service; Board on 
health sciences policy; Institute of medicine; Evolution of translational OMICS: lessons 
learned and the path foreward.: The National Academies Press (Washington, D.C.), 2012. 
 40.  Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting Recommendations for 
Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med 
2012; 9: e1001216. 
19 
 
 41.  Pignata S, Scambia G, Katsaros D et al. Carboplatin plus paclitaxel once a week versus 
every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, 
multicentre, open-label, phase 3 trial. Lancet Oncol 2014; 15: 396-405. 
 42.  Callari M, Dugo M, Musella V et al. Comparison of microarray platforms for measuring 








Clinical and pathological characteristics of patients included in the three case materials 
 





  N° (179) % N° (263) % N° (452) % 
Age, years 
 
          
     mean, median 58, 59 55, 56 59, 58 
     range 28-78 25-85 26-87 
Histology 
 
          
     Serous 124 69 190 72 452 100 
     Undifferentiated 10 6 23 9 na   
     Endometroid 24 13 26 10 na   
     Mucinous 0 0 1 0 na   
     Clear Cells 6 3 7 3 na   
     Others + Mixed 13 7 15 6 na   
Missing information 2 1 1 0 na   
Stage (FIGO) 
 
          
     I 17 9 16 6 11 2 
     II 15 8 9 3 27 6 
     III 123 69 212 81 350 77 
     IV 24 13 26 10 63 14 
Missing Information 
 
      1 0 
Grade 
 
          
     border line 0 0 3 1 1 
 
     1, well differentiated 5 3 7 3 5 1 
     2, moderately differentiated 27 15 51 19 55 12 
     3, poorly differentiated 126 70 177 67 382 84 
     Undifferentiated 10 6 23 9 0 0 
     GX 0 0 0 0 8 2 
Missing information 11 6 2 1 1   
Amount of residual disease 
 
          
     NED 73 41 76 29 102 23 
     <1 cm, mRD 42 23 85 32 208 46 
     >1 cm, GRD 53 30 101 39 100 22 
    not operated 11 6 0 0 0 0 
Missing information 0 0 1 0 42 9 
Median follow up (months) 73 (IQR 60-88) 44 (IQR 24-71) 56 (IQR 25-86) 
 
na=not applicable; FIGO=International federation of Gynecology and Obstetrics; NED=not 






List of the 35 miRNAs entered into the prognostic model 
 




Hazard ratio 0·95 CI Weight (wi) 
hsa-miR-193a-5p <0·0001  100 1·977 1·287-2·974 0·010396 
hsa-miR-508-3p <0·0001  100 0·747 0·756-0·958 –0·045965 
hsa-miR-509-5p <0·0001  100 0·684 0·731-0·918 –0·035031 
hsa-miR-514a-3p <0·0001  100 0·811 1·183-2·367 –0·058425 
hsa-miR-506-3p <0·0001  100 0·635 1·031-1·512 –0·032425 
hsa-miR-507 <0·0001  100 0·588 1·492-2·612 –0·026022 
hsa-miR-509-3p <0·0001  100 0·783 1·059-2·14 –0·049717 
hsa-miR-592 0·00015 100 0·255 1·126-2·356 –0·002782 
hsa-miR-29c-5p 0·00071 100 1·595 0·706-0·925 0·005566 
hsa-miR-513b-5p 0·00072 100 0·817 0·678-0·911 –0·028496 
hsa-miR-513a-5p 0·00074 100 0·766 0·694-0·905 –0·021663 
hsa-miR-200c-3p 0·0015 100 0·793 1·181-2·278 –0·027508 
hsa-miR-141-3p 0·0017 100 0·819 1·153-2·700 –0·032066 
hsa-miR-200b-3p 0·0027 100 0·786 1·232-2·065 –0·028151 
hsa-miR-423-5p 0·0029 90 1·765 1·241-3·165 0·005948 
hsa-miR-486-5p 0·0030 90 1·345 1·032-1·52 0·015239 
hsa-miR-200a-3p 0·0032 100 0·808 1·206-2·854 –0·032221 
hsa-miR-23a-5p 0·0052 80 1·641 1·226-2·537 0·006169 
hsa-miR-330-3p 0·0061 80 1·856 0·727-0·958 0·004021 
hsa-miR-30b-3p 0·0064 100 1·983 1·062-1·531 0·002938 
hsa-miR-484 0·0079 80 1·6 1·160-2·206 0·002136 
hsa-miR-769-5p 0·0082 70 1·762 1·121-1·612 0·002445 
hsa-miR-135b-5p 0·0089 80 0·851 0·479-0·841 –0·024577 
hsa-miR-100-3p 0·0090 90 1·958 0·429-0·805 0·003563 
hsa-miR-99b-5p 0·0094 70 1·35 0·637-0·874 0·007011 
hsa-miR-143-5p 0·0096 80 1·674 0·685-0·895 0·00264 
hsa-miR-429 0·012 60 0·835 0·555-0·843 –0·030913 
hsa-miR-151a-3p 0·013 60 1·363 0·662-0·886 0·004522 
hsa-miR-574-5p 0·016 50 1·283 0·732-0·912 0·005807 
hsa-miR-452-5p 0·017 60 1·276 0·726-0·907 0·00919 
hsa-miR-29a-5p 0·018 50 1·765 1·049-1·568 0·000855 
hsa-miR-195-3p 0·019 40 1·629 0·099-0·661 0·005412 
hsa-miR-890 0·023 40 0·085 1·186-2·614 –0·000287 
hsa-miR-30d-5p 0·023 40 1·253 0·010-0·717 0·000766 
hsa-miR-193b-5p 0·024 60 1·506 1·075-1·695 0·005293 
 
The unique miRNA ID according to miRBase 21·0, p values, percentages of cross validation 
support, individual hazard ratios, 0·95 Confidence Interval (CI) and weights are reported. 
miRNAs whose expression is associated with poor prognosis are shown in red, while those 




Univariate and multivariable analysis (Cox regression) of progression-free survival for clinical 
and biological variables in the test set (OC179) and validation sets (OC263 and OC452). 
 




Univariate analysis Multivariable analysis 




Stage       
III–IV vs I–II 4·74 2·40–9·36 <0·0001 3·70 1·83–7·49 <0·00028 
Surgical debulking       
SOD vs OD 2·10 1·46–3·00 <0·0001 1·46 1·01–2·12 0·043 
miRNA predictor       




Stage       
III–IV vs I–II 2·16 1·25–3·73 <0·0057 2·16 1·21–3·90 0·0097 
Surgical debulking       
SOD vs OD 2·23 1·67–2·97 <0·0001 1·53 1·13–2·08 0·0060 
miRNA predictor       




Stage       
III–IV vs I–II 1·68 1·02–2·78 0·04 1·79 1·04–3·08 0·035 
Surgical debulking       
SOD vs OD 1·37 1·07–1·75 0·012 1·27 0·99-1·63 0·059 
miRNA predictor       




Univariate and multivariable analysis (Cox regression) of progression-free survival for 











Univariate analysis Multivariable analysis 




Stage       
III–IV vs I–II 2·45 1·20–5·00 0·013 2·37 1·10–5·12 0·028 
Surgical debulking       
SOD vs OD 2·07 1·53–2·81 <0·0001 1·50 1·10–2·06 0·011 
miRNA predictor       





Univariate and multivariable analysis (Cox regression) of progression-free survival for clinical 
and biological variables in HGSOC cases (n=185) of OC263 case materials 
 






Univariate analysis Multivariable analysis 




Stage       
III–IV vs I–II 2·81 1·15–6·90 0·023 2·67 0·96–7·38 0·058 
Surgical debulking       
SOD vs OD 2·10 1·50–2·95 <0·0001 1·62 1·14–2·29 0·0071 
miRNA predictor       




Figure 1. Characteristics of the case materials, miRNA platforms and Chip arrays used for 
development of a miRNA classifier able to predict EOC patients’ risk of relapse. FFPE = formalin-
fixed paraffin embedded samples. The inter-platform reproducibility of miRNA microarray profiles 
was demonstrated by our previous study by Callari et al. 
42
. 
Figure 2. Expression heat map of the 35 miRNAs entering into the predictive model. Columns = 
patients (179) and rows = miRNAs (35), sorted on the basis of the established index. The plot above 
summarises the specific MiROvaR risk-score index for each sample. Blue: miRNAs whose 
expression is associated with a good prognosis. Red: miRNAs whose expression is associated with 
a poor prognosis.  
Figure 3. Kaplan–Meier curves of patients stratified according to the miRNA predictor. A. 
MiROvaR stratification of patients included in the OC179 training set. MiROvaR high-risk (red 
line) and MiROvaR low-risk (blue line) curves were compared using a log-rank test. Nyr = not yet 
reached. B, C. The ability of MiROvaR to classify EOC patients for risk of progression was 
validated in two independent data sets. Kaplan–Meier curves of OC263 (B) and OC452 (C) patients 
stratified according to the miRNA predictor are shown. Blue lines = MiROvaR low-risk patients; 
red lines = MiROvaR high-risk patients. 
Figure 4. Ability of MiROvaR to predict the risk of progression in Type-II (A) and high-grade 
serous ovarian cancer (HGSOC), B) subpopulations of the OC263 validation set. Blue lines = 
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Low 169 115 19 17-27
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90 58 43 31 15 4 1
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